Evidence map›Paper›PMID 29637300›Full record

ReviewCurrent oncology reports2018

Single-Cell RNA-Sequencing in Glioma.

Eli Johnson, Katherine L Dickerson, Ian D Connolly, Melanie Hayden Gephart

Abstract readReview
In one paragraph

Review in Current oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.Journal of experimental & clinical cancer research : CR · 2020
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Potential application of cell reprogramming techniques for cancer research.Cellular and molecular life sciences : CMLS · 2019
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eli JohnsonStanford University School of Medicine, Stanford, CA, USA.
Katherine L DickersonStanford University School of Medicine, Stanford, CA, USA.
Ian D ConnollyStanford University School of Medicine, Stanford, CA, USA.
Melanie Hayden GephartDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. mghayden@stanford.edu.

Funding

(PQ1) Identifying and targeting human glioblastoma migrating in the peritumoral nicheR01CA216054 · NCI · STANFORD UNIVERSITY · PI HAYDEN GEPHART, MELANIE · 2017 to 2021
$1.7M
NCI NIH HHS R01 CA216054
6 · The paper itself

Abstract

purpose of reviewIn this review, we seek to summarize the literature concerning the use of single-cell RNA-sequencing for CNS gliomas. RECENT

findingsSingle-cell analysis has revealed complex tumor heterogeneity, subpopulations of proliferating stem-like cells and expanded our view of tumor microenvironment influence in the disease process. Although bulk RNA-sequencing has guided our initial understanding of glioma genetics, this method does not accurately define the heterogeneous subpopulations found within these tumors. Single-cell techniques have appealing applications in cancer research, as diverse cell types and the tumor microenvironment have important implications in therapy. High cost and difficult protocols prevent widespread use of single-cell RNA-sequencing; however, continued innovation will improve accessibility and expand our of knowledge gliomas.

Indexed as

Biomarkers, TumorBrain NeoplasmsGliomaHigh-Throughput Nucleotide SequencingHumansPrognosisSingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorGliomaRNA-sequencingSingle-cell

Identifiers

PMID29637300
PMCPMC8403493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.